| Sample | Title | Value | Rank |
|---|
| GSM1256968 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 1 | 1304.64 | 97 |
| GSM1256969 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 2 | 688.93 | 94 |
| GSM1256970 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 3 | 1208.01 | 97 |
| GSM1256971 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 4 | 937.314 | 96 |
| GSM1256988 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 55 before YFV | 20.6027 | 56 |
| GSM1256991 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 55 seven days after YFV | 695.011 | 95 |
| GSM1256989 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 56 before YFV | 34.4124 | 63 |
| GSM1256992 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 56 seven days after YFV | 585.534 | 94 |
| GSM1256990 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 57 before YFV | 23.7877 | 57 |
| GSM1256993 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 57 seven days after YFV | 237.638 | 87 |